Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke : A MR CLEAN Registry Substudy
© 2022 American Academy of Neurology..
BACKGROUND AND OBJECTIVES: To explore clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment (EVT).
METHODS: Using data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, we compared patients with active cancer (defined as cancer diagnosed within 12 months before stroke, metastatic disease, or current cancer treatment) to patients without cancer. Outcomes were 90-day modified Rankin Scale (mRS) score, mortality, successful reperfusion (expanded Treatment in Cerebral Infarction score ≥2b), symptomatic intracranial hemorrhage (sICH), and recurrent stroke. Subgroup analyses were performed in patients with a prestroke mRS score of 0 or 1 and according to treatment setting (curative or palliative). Analyses were adjusted for prognostic variables.
RESULTS: Of 2,583 patients who underwent EVT, 124 (4.8%) had active cancer. They more often had prestroke disability (mRS score ≥2: 34.1% vs 16.6%). The treatment setting was palliative in 25.3% of the patients. There was a shift toward worse functional outcome at 90 days in patients with active cancer (adjusted common odds ratio [acOR] 2.2, 95% confidence interval [CI] 1.5-3.2). At 90 days, patients with active cancer were less often independent (mRS score 0-2: 22.6% vs 42.0%, adjusted OR [aOR] 0.5, 95% CI 0.3-0.8) and more often dead (52.2% vs 26.5%, aOR 3.2, 95% CI 2.1-4.9). Successful reperfusion (67.8% vs 60.5%, aOR 1.4, 95% CI 1.0-2.1) and sICH rates (6.5% vs 5.9%, aOR 1.1, 95% CI 0.5-2.3) did not differ. Recurrent stroke within 90 days was more common in patients with active cancer (4.0% vs 1.3%, aOR 3.1, 95% CI 1.2-8.1). The sensitivity analysis of patients with a prestroke mRS score of 0 or 1 showed that patients with active cancer still had a worse outcome at 90 days (acOR 1.9, 95% CI 1.2-3.0). Patients with active cancer in a palliative treatment setting regained functional independence less often compared to patients in a curative setting (18.2% vs 32.1%), and mortality was higher (81.8% vs 39.3%).
DISCUSSION: Despite similar technical success, patients with active cancer had significantly worse outcomes after EVT for AIS. Moreover, they had an increased risk of recurrent stroke. Nevertheless, about a quarter of the patients regained functional independence, and the risk of other complications, most notably sICH, was not increased.
CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that patients with active cancer undergoing EVT for AIS have worse functional outcomes at 90 days compared to those without active cancer.
| Errataetall: |
CommentIn: Neurology. 2022 Jul 26;99(4):174-175. - PMID 35879088 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Neurology - 98(2022), 10 vom: 08. März, Seite e993-e1001 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verschoof, Merelijne A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 06.04.2022 Date Revised 29.08.2022 published: Print-Electronic CommentIn: Neurology. 2022 Jul 26;99(4):174-175. - PMID 35879088 Citation Status MEDLINE |
|---|
| doi: |
10.1212/WNL.0000000000013316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335523056 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335523056 | ||
| 003 | DE-627 | ||
| 005 | 20231225230037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000013316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335523056 | ||
| 035 | |a (NLM)35017306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verschoof, Merelijne A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke |b A MR CLEAN Registry Substudy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2022 | ||
| 500 | |a Date Revised 29.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Neurology. 2022 Jul 26;99(4):174-175. - PMID 35879088 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 American Academy of Neurology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: To explore clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment (EVT) | ||
| 520 | |a METHODS: Using data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, we compared patients with active cancer (defined as cancer diagnosed within 12 months before stroke, metastatic disease, or current cancer treatment) to patients without cancer. Outcomes were 90-day modified Rankin Scale (mRS) score, mortality, successful reperfusion (expanded Treatment in Cerebral Infarction score ≥2b), symptomatic intracranial hemorrhage (sICH), and recurrent stroke. Subgroup analyses were performed in patients with a prestroke mRS score of 0 or 1 and according to treatment setting (curative or palliative). Analyses were adjusted for prognostic variables | ||
| 520 | |a RESULTS: Of 2,583 patients who underwent EVT, 124 (4.8%) had active cancer. They more often had prestroke disability (mRS score ≥2: 34.1% vs 16.6%). The treatment setting was palliative in 25.3% of the patients. There was a shift toward worse functional outcome at 90 days in patients with active cancer (adjusted common odds ratio [acOR] 2.2, 95% confidence interval [CI] 1.5-3.2). At 90 days, patients with active cancer were less often independent (mRS score 0-2: 22.6% vs 42.0%, adjusted OR [aOR] 0.5, 95% CI 0.3-0.8) and more often dead (52.2% vs 26.5%, aOR 3.2, 95% CI 2.1-4.9). Successful reperfusion (67.8% vs 60.5%, aOR 1.4, 95% CI 1.0-2.1) and sICH rates (6.5% vs 5.9%, aOR 1.1, 95% CI 0.5-2.3) did not differ. Recurrent stroke within 90 days was more common in patients with active cancer (4.0% vs 1.3%, aOR 3.1, 95% CI 1.2-8.1). The sensitivity analysis of patients with a prestroke mRS score of 0 or 1 showed that patients with active cancer still had a worse outcome at 90 days (acOR 1.9, 95% CI 1.2-3.0). Patients with active cancer in a palliative treatment setting regained functional independence less often compared to patients in a curative setting (18.2% vs 32.1%), and mortality was higher (81.8% vs 39.3%) | ||
| 520 | |a DISCUSSION: Despite similar technical success, patients with active cancer had significantly worse outcomes after EVT for AIS. Moreover, they had an increased risk of recurrent stroke. Nevertheless, about a quarter of the patients regained functional independence, and the risk of other complications, most notably sICH, was not increased | ||
| 520 | |a CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that patients with active cancer undergoing EVT for AIS have worse functional outcomes at 90 days compared to those without active cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Groot, Adrien E |e verfasserin |4 aut | |
| 700 | 1 | |a de Bruijn, Sebastiaan F T M |e verfasserin |4 aut | |
| 700 | 1 | |a Roozenbeek, Bob |e verfasserin |4 aut | |
| 700 | 1 | |a van der Worp, H Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Dippel, Diederik W J |e verfasserin |4 aut | |
| 700 | 1 | |a Emmer, Bart J |e verfasserin |4 aut | |
| 700 | 1 | |a Roosendaal, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Majoie, Charles B L M |e verfasserin |4 aut | |
| 700 | 1 | |a Roos, Yvo B W E M |e verfasserin |4 aut | |
| 700 | 1 | |a Coutinho, Jonathan M |e verfasserin |4 aut | |
| 700 | 0 | |a MR CLEAN Registry Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Dippel, Diederik W J |e investigator |4 oth | |
| 700 | 1 | |a van der Lugt, Aad |e investigator |4 oth | |
| 700 | 1 | |a Majoie, Charles B L M |e investigator |4 oth | |
| 700 | 1 | |a Roos, Yvo B W E M |e investigator |4 oth | |
| 700 | 1 | |a van Oostenbrugge, Robert J |e investigator |4 oth | |
| 700 | 1 | |a van Zwam, Wim H |e investigator |4 oth | |
| 700 | 1 | |a Boiten, Jelis |e investigator |4 oth | |
| 700 | 1 | |a Vos, Jan Albert |e investigator |4 oth | |
| 700 | 1 | |a Jansen, Ivo G H |e investigator |4 oth | |
| 700 | 1 | |a Mulder, Maxim J H L |e investigator |4 oth | |
| 700 | 1 | |a Goldhoorn, Robert-Jan B |e investigator |4 oth | |
| 700 | 1 | |a Schonewille, Wouter J |e investigator |4 oth | |
| 700 | 1 | |a Coutinho, Jonathan M |e investigator |4 oth | |
| 700 | 1 | |a Wermer, Marieke J H |e investigator |4 oth | |
| 700 | 1 | |a van Walderveen, Marianne A A |e investigator |4 oth | |
| 700 | 1 | |a Staals, Julie |e investigator |4 oth | |
| 700 | 1 | |a Hofmeijer, Jeannette |e investigator |4 oth | |
| 700 | 1 | |a Martens, Jasper M |e investigator |4 oth | |
| 700 | 1 | |a Lycklama À Nijeholt, Geert J |e investigator |4 oth | |
| 700 | 1 | |a Roozenbeek, Bob |e investigator |4 oth | |
| 700 | 1 | |a Emmer, Bart J |e investigator |4 oth | |
| 700 | 1 | |a de Bruijn, Sebastiaan F |e investigator |4 oth | |
| 700 | 1 | |a van Dijk, Lukas C |e investigator |4 oth | |
| 700 | 1 | |a Bart van der Worp, H |e investigator |4 oth | |
| 700 | 1 | |a Lo, Rob H |e investigator |4 oth | |
| 700 | 1 | |a van Dijk, Ewoud J |e investigator |4 oth | |
| 700 | 1 | |a Boogaarts, Hieronymus D |e investigator |4 oth | |
| 700 | 1 | |a de Kort, Paul L M |e investigator |4 oth | |
| 700 | 1 | |a Peluso, Jo J P |e investigator |4 oth | |
| 700 | 1 | |a van den Berg, Jan S P |e investigator |4 oth | |
| 700 | 1 | |a van Hasselt, Boudewijn A A M |e investigator |4 oth | |
| 700 | 1 | |a Aerden, Leo A M |e investigator |4 oth | |
| 700 | 1 | |a Dallinga, René J |e investigator |4 oth | |
| 700 | 1 | |a Uyttenboogaart, Maarten |e investigator |4 oth | |
| 700 | 1 | |a Eshghi, Omid |e investigator |4 oth | |
| 700 | 1 | |a Schreuder, Tobien H C M L |e investigator |4 oth | |
| 700 | 1 | |a Heijboer, Roel J J |e investigator |4 oth | |
| 700 | 1 | |a Keizer, Koos |e investigator |4 oth | |
| 700 | 1 | |a Yo, Lonneke S F |e investigator |4 oth | |
| 700 | 1 | |a den Hertog, Heleen M |e investigator |4 oth | |
| 700 | 1 | |a Sturm, Emiel J C |e investigator |4 oth | |
| 700 | 1 | |a Sprengers, Marieke E S |e investigator |4 oth | |
| 700 | 1 | |a Jenniskens, Sjoerd F M |e investigator |4 oth | |
| 700 | 1 | |a van den Berg, René |e investigator |4 oth | |
| 700 | 1 | |a Yoo, Albert J |e investigator |4 oth | |
| 700 | 1 | |a Beenen, Ludo F M |e investigator |4 oth | |
| 700 | 1 | |a Postma, Alida A |e investigator |4 oth | |
| 700 | 1 | |a Roosendaal, Stefan D |e investigator |4 oth | |
| 700 | 1 | |a van der Kallen, Bas F W |e investigator |4 oth | |
| 700 | 1 | |a van den Wijngaard, Ido R |e investigator |4 oth | |
| 700 | 1 | |a van Es, Adriaan C G M |e investigator |4 oth | |
| 700 | 1 | |a Bot, Joost |e investigator |4 oth | |
| 700 | 1 | |a Doormaal, Pieter-Jan van |e investigator |4 oth | |
| 700 | 1 | |a Flach, H Zwenneke |e investigator |4 oth | |
| 700 | 1 | |a Lingsma, Hester F |e investigator |4 oth | |
| 700 | 1 | |a Ghannouti, Naziha El |e investigator |4 oth | |
| 700 | 1 | |a Ghannouti, Naziha El |e investigator |4 oth | |
| 700 | 1 | |a Puppels, Corina |e investigator |4 oth | |
| 700 | 1 | |a Pellikaan, Wilma |e investigator |4 oth | |
| 700 | 1 | |a Sprengers, Rita |e investigator |4 oth | |
| 700 | 1 | |a Sprengers, Rita |e investigator |4 oth | |
| 700 | 1 | |a de Meris, Joke |e investigator |4 oth | |
| 700 | 1 | |a Vermeulen, Tamara |e investigator |4 oth | |
| 700 | 1 | |a Geerlings, Annet |e investigator |4 oth | |
| 700 | 1 | |a van Vemde, Gina |e investigator |4 oth | |
| 700 | 1 | |a Simons, Tiny |e investigator |4 oth | |
| 700 | 1 | |a van Rijswijk, Cathelijn |e investigator |4 oth | |
| 700 | 1 | |a Messchendorp, Gert |e investigator |4 oth | |
| 700 | 1 | |a Bongenaar, Hester |e investigator |4 oth | |
| 700 | 1 | |a Bodde, Karin |e investigator |4 oth | |
| 700 | 1 | |a Kleijn, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Lodico, Jasmijn |e investigator |4 oth | |
| 700 | 1 | |a Droste, Hanneke |e investigator |4 oth | |
| 700 | 1 | |a Wollaert, M |e investigator |4 oth | |
| 700 | 1 | |a Jeurrissen, D |e investigator |4 oth | |
| 700 | 1 | |a Bos, Erna |e investigator |4 oth | |
| 700 | 1 | |a Drabbe, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Zweedijk, Berber |e investigator |4 oth | |
| 700 | 1 | |a Khalilzada, Mostafa |e investigator |4 oth | |
| 700 | 1 | |a Venema, Esmee |e investigator |4 oth | |
| 700 | 1 | |a Chalos, Vicky |e investigator |4 oth | |
| 700 | 1 | |a Compagne, Kars C J |e investigator |4 oth | |
| 700 | 1 | |a Geuskens, Ralph R |e investigator |4 oth | |
| 700 | 1 | |a van Straaten, Tim |e investigator |4 oth | |
| 700 | 1 | |a Ergezen, Saliha |e investigator |4 oth | |
| 700 | 1 | |a Harmsma, Roger R M |e investigator |4 oth | |
| 700 | 1 | |a Muijres, Daan |e investigator |4 oth | |
| 700 | 1 | |a de Jong, Anouk |e investigator |4 oth | |
| 700 | 1 | |a Hinsenveld, Wouter |e investigator |4 oth | |
| 700 | 1 | |a Berkhemer, Olvert A |e investigator |4 oth | |
| 700 | 1 | |a Boers, Anna M M |e investigator |4 oth | |
| 700 | 1 | |a Huguet, J |e investigator |4 oth | |
| 700 | 1 | |a Groot, P F C |e investigator |4 oth | |
| 700 | 1 | |a Mens, Marieke A |e investigator |4 oth | |
| 700 | 1 | |a van Kranendonk, Katinka R |e investigator |4 oth | |
| 700 | 1 | |a van Kranendonk, Katinka R |e investigator |4 oth | |
| 700 | 1 | |a Kappelhof, Manon |e investigator |4 oth | |
| 700 | 1 | |a Tolhuijsen, Manon L |e investigator |4 oth | |
| 700 | 1 | |a Alves, Heitor |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d 1951 |g 98(2022), 10 vom: 08. März, Seite e993-e1001 |w (DE-627)NLM000034355 |x 1526-632X |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2022 |g number:10 |g day:08 |g month:03 |g pages:e993-e1001 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1212/WNL.0000000000013316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2022 |e 10 |b 08 |c 03 |h e993-e1001 | ||